Volume 4, Issue 4

Treatment Considerations for Aging Patients

In this issue:

As people with MS age, how does their response to their long-term DMT change? Is there a time when disease-modifying therapy can be safely discontinued? In which patients? At what age? What role do comorbidities play in making these decisions? 

Join us as we discuss these questions with Dr. Burcu Zeydan from the Mayo Clinic in this eMultipleSclerosis Review podcast.

Learning objectives:

  • Describe the role of aging-related mechanisms in MS management and DMT discontinuation.  
  • Discuss the benefit-risk ratio in DMT discontinuation, taking into account the comorbidities commonly present in older patients with MS. 

Author:

Burcu Zeydan, MD
Burcu Zeydan, MD
Assistant Professor of Neurology and Radiology
Mayo Clinic College of Medicine
Rochester, MN

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: January 6, 2022
Expiration date: January 5, 2024